Vincent Cryns Explained

Vincent Cryns
Workplaces:University of Wisconsin-Madison
Alma Mater:Harvard College and Harvard Medical School, Boston, MA
Thesis1 Title:and
Thesis2 Title:)-->
Thesis1 Url:and
Thesis2 Url:)-->
Thesis1 Year:and
Thesis2 Year:)-->
Known For:cancer
Spouses:)-->
Partners:)-->

Vincent Cryns is the Chief of the Division of Endocrinology, Diabetes & Metabolism[1] at the University of Wisconsin School of Medicine and Public Health and holds the Marian A. and Rodney P. Burgenske Chair in Diabetes Research.[2] [3]

Early life

Cryns attended East High School in East Amherst, New York,[4] received his bachelor's degree from Harvard College and his M.D. from Harvard Medical School in 1987.

Career

After completing residency and specialty training at Massachusetts General Hospital in Boston, Massachusetts, he became an assistant professor at Northwestern University. He later moved to Madison, Wisconsin to chair the Division of Endocrinology, Diabetes, and Metabolism at the University of Wisconsin School of Medicine and Public Health.

Cryns is on the editorial board of the American Journal of Cancer Research,[5] the Journal of Drug Metabolism and Toxicology, the Journal of Signal Transduction, the Journal of Stem Cell Research and Therapy, and Molecular Endocrinology. In 2010, Cryns served as the associate editor-in-chief of the American Journal of Cancer Research.

Cryns's lab is focused on understanding apoptosis, the process by which cancer cells die, and has published on how methionine restriction sensitizes cancer cells to TRAIL receptor agonists.[6] The Cryns lab also showed that the metastasis of breast cancer to the brain and lungs is dependent upon the protein αB-crystallin.[7] [8] [9]

Notes and References

  1. Web site: UW Endocrinology, Diabetes and Metabolism .
  2. Web site: Breast Cancer Research Foundation.
  3. Web site: UWSMPH Directory.
  4. Web site: Bio - Cryns, Vincent - WEDF. www.wedf.org. 2015-09-13.
  5. American Journal of Cancer Research: Editorial Board (2011). American Journal of Cancer Research. 2011-01-01. 2156-6976. 3195929. 22016829. 817–822. 1. 6. Joseph H.. Antin. Andrew E.. Aplin. Sheue-Yann. Cheng. Michael R.. Emmert-Buck. Vincent L.. Cryns. Dengshun. Wang.
  6. Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression. Clinical Cancer Research . 2015-06-15. 1078-0432. 4470820. 25724522. 2780–2791. 21. 12. 10.1158/1078-0432.CCR-14-2792. Elena. Strekalova. Dmitry. Malin. David M.. Good. Vincent L.. Cryns.
  7. αB-crystallin: a novel regulator of breast cancer metastasis to the brain. Clinical Cancer Research . 2014-01-01. 1078-0432. 3973485. 24132917. 56–67. 20. 1. 10.1158/1078-0432.CCR-13-1255. Dmitry. Malin. Elena. Strekalova. Vladimir. Petrovic. Allison M.. Deal. Abraham. Al Ahmad. Barbara. Adamo. C. Ryan. Miller. Andrey. Ugolkov. Chad. Livasy.
  8. ERK-regulated αB-crystallin induction by matrix detachment inhibits anoikis and promotes lung metastasis in vivo. Oncogene. 2015-02-16. 1476-5594. 4537846. 25684139. 10.1038/onc.2015.12. D.. Malin. E.. Strekalova. V.. Petrovic. H.. Rajanala. B.. Sharma. A.. Ugolkov. W. J.. Gradishar. V. L.. Cryns. 34. 45. 5626–34.
  9. Moyano. Jose V.. Evans. Joseph R.. Chen. Feng. Lu. Meiling. Werner. Michael E.. Yehiely. Fruma. Diaz. Leslie K.. Turbin. Dmitry. Karaca. Gamze. January 2006. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. The Journal of Clinical Investigation. 116. 1. 261–270. 10.1172/JCI25888. 0021-9738. 1323258. 16395408.